Literature DB >> 21051833

[Expression of checkpoint kinase 1 and polo-like kinase 1 and its clinicopathological significance in benign and malignant lesions of the stomach].

Hongliang Yao1, Zhulin Yang, Yongguo Li.   

Abstract

OBJECTIVE: To determine the expressive level of checkpoint kinase 1 (CHK1) and polo-like kinase 1 (PLK1) and to detect their clinicopathological significance in benign and malignant lesions of the stomach.
METHODS: Envision Tm immunohistochemistry was used to detect the expression level of CHK1 and PLK1 in conventional paraffin-embedded sections from specimens of primary foci (n=59)and metastatic foci of lymph node (n=42) of gastric cancer, peritumoral tissues (n=20), and benign lesions of the stomach (n=95).
RESULTS: The positive rates of CHK1 were significantly higher in gastric cancer than that in different types of benign lesions(P<0.01). The positive rates of PLK1 were significantly higher in gastric cancer than that in peritumoral tissues (P<0.05) and different types of benign lesions (P<0.01), and the positive cases of PLK1 in benign lesion showed atypical hyperplasia. No significant difference of CHK1 and PLK1 expression was found between metastatic foci and corresponding primary foci (P>0.05). The positive rates of CHK1 and PLK1 were significantly lower in the non-metastatic lymph node than that in the metastatic lymph node (P<0.05). The positive rate of CHK1 was significantly lower in histologic grade II than that in the histologic grade III+IV (P<0.05). Positive correlation was found between the expression of CHK1 and PLK1 in gastric cancer tissues (P<0.01).
CONCLUSION: The expression level of CHK1 and /or PLK1 might be important biological markers of kinases to reflect the carcinogenesis, progression, biological behaviors, and guide clinical auxiliary treatment of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21051833     DOI: 10.3969/j.issn.1672-7347.2010.10.008

Source DB:  PubMed          Journal:  Zhong Nan Da Xue Xue Bao Yi Xue Ban        ISSN: 1672-7347


  9 in total

1.  Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non-small cell lung cancer.

Authors:  Svetlana Grabauskiene; Edward J Bergeron; Guoan Chen; Dafydd G Thomas; Thomas J Giordano; David G Beer; Meredith A Morgan; Rishindra M Reddy
Journal:  J Surg Res       Date:  2013-12-18       Impact factor: 2.192

Review 2.  Roles of Chk1 in cell biology and cancer therapy.

Authors:  Youwei Zhang; Tony Hunter
Journal:  Int J Cancer       Date:  2013-05-28       Impact factor: 7.396

3.  Conformational Change of Human Checkpoint Kinase 1 (Chk1) Induced by DNA Damage.

Authors:  Xiangzi Han; Jinshan Tang; Jingna Wang; Feng Ren; Jinhua Zheng; Megan Gragg; Philip Kiser; Paul S H Park; Krzysztof Palczewski; Xinsheng Yao; Youwei Zhang
Journal:  J Biol Chem       Date:  2016-04-18       Impact factor: 5.157

4.  Checkpoint Kinase 1 Expression Predicts Poor Prognosis in Nigerian Breast Cancer Patients.

Authors:  Henry Okuchukwu Ebili; Victoria O Iyawe; Kikelomo Rachel Adeleke; Babatunde Abayomi Salami; Adekunbiola Aina Banjo; Chris Nolan; Emad Rakha; Ian Ellis; Andrew Green; Ayodeji Olayinka Johnson Agboola
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

5.  CHK1 expression in Gastric Cancer is modulated by p53 and RB1/E2F1: implications in chemo/radiotherapy response.

Authors:  J Bargiela-Iparraguirre; L Prado-Marchal; M Fernandez-Fuente; A Gutierrez-González; J Moreno-Rubio; M Muñoz-Fernandez; M Sereno; R Sanchez-Prieto; R Perona; I Sanchez-Perez
Journal:  Sci Rep       Date:  2016-02-12       Impact factor: 4.379

6.  Ataxin-3 promotes genome integrity by stabilizing Chk1.

Authors:  Yingfeng Tu; Hongmei Liu; Xuefei Zhu; Hongyan Shen; Xiaolu Ma; Fengli Wang; Min Huang; Juanjuan Gong; Xiaoling Li; Yun Wang; Caixia Guo; Tie-Shan Tang
Journal:  Nucleic Acids Res       Date:  2017-05-05       Impact factor: 16.971

7.  The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis.

Authors:  Hefei Li; Haibo Wang; Zhenqing Sun; Qiang Guo; Hongyun Shi; Youchao Jia
Journal:  Biosci Rep       Date:  2017-07-19       Impact factor: 3.840

8.  Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro.

Authors:  Zhihui Wang; Mette S Førsund; Claes G Trope; Jahn M Nesland; Ruth Holm; Ana Slipicevic
Journal:  Cancer Med       Date:  2018-07-02       Impact factor: 4.452

9.  The anticipating value of PLK1 for diagnosis, progress and prognosis and its prospective mechanism in gastric cancer: a comprehensive investigation based on high-throughput data and immunohistochemical validation.

Authors:  Peng Lin; Dan-Dan Xiong; Yi-Wu Dang; Hong Yang; Yun He; Dong-Yue Wen; Xin-Gan Qin; Gang Chen
Journal:  Oncotarget       Date:  2017-09-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.